Nanoviricides (NNVC) Times Interest Earned (2013 - 2025)
Nanoviricides (NNVC) posted Times Interest Earned of -$449171.2 for Q3 2025, down 1138.18% sequentially from -$36276.7 in Q1 2025, and down 935.08% YoY from $53788.0 in Q3 2024.
Nanoviricides (NNVC) Times Interest Earned (2013 - 2025) Analysis & Trends
Nanoviricides has reported Times Interest Earned for 13 years, with the latest figure at -$449171.2 in Q3 2025.
- Quarterly Times Interest Earned fell 935.08% year-over-year to -$449171.2 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$2.1 million (down 1454.27% YoY) and the FY2025 annual result came in at -$351.72, down 105.71% from the prior year.
- Times Interest Earned fell to -$449171.2 in Q3 2025 per NNVC's latest filing, from -$36276.7 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$55.67 in Q3 2023 and troughed at -$449171.2 in Q3 2025.
- A 5-year average of -$42242.6 and a median of -$2425.4 in 2021 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned jumped 99.16% in 2023, then slumped 77849.41% in 2024.
- Over 5 years, Times Interest Earned stood at -$20216.6 in 2021, then gained by 3.49% to -$19510.6 in 2022, then surged by 99.16% to -$164.08 in 2023, then slumped by 8322.07% to -$13819.1 in 2024, then tumbled by 3150.36% to -$449171.2 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$449171.2, -$36276.7, and -$13819.1 for Q3 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -449,171.25 |
| Mar 31, 2025 | -36,276.71 |
| Dec 31, 2024 | -13,819.13 |
| Sep 30, 2024 | -43,394.99 |
| Dec 31, 2023 | -164.08 |
| Sep 30, 2023 | -55.67 |
| Dec 31, 2022 | -19,510.57 |
| Sep 30, 2022 | -1,922.23 |
| Jun 30, 2022 | -1,068.40 |
| Mar 31, 2022 | -714.58 |
| Dec 31, 2021 | -20,216.59 |
| Sep 30, 2021 | -2,928.66 |
| Jun 30, 2021 | -1,316.16 |
| Mar 31, 2021 | -837.65 |
| Dec 31, 2020 | -61.46 |
| Sep 30, 2020 | -51.71 |
| Jun 30, 2020 | 1,049.73 |
| Mar 31, 2020 | 1,065.53 |
| Dec 31, 2019 | -395.65 |
| Jun 30, 2018 | -7.25 |